TY - JOUR U1 - Wissenschaftlicher Artikel A1 - Tian, Yu A1 - Lin, Yi A1 - Qu, Conghui A1 - Arndt, Volker A1 - Baurley, James W. A1 - Berndt, Sonja I. A1 - Bien, Stephanie A. A1 - Bishop, D. Timothy A1 - Brenner, Hermann A1 - Buchanan, Daniel D. A1 - Budiarto, Arif A1 - Campbell, Peter T. A1 - Carreras-Torres, Robert A1 - Casey, Graham A1 - Chan, Andrew T. A1 - Chen, Rui A1 - Chen, Xuechen A1 - Conti, David V. A1 - Díez-Obrero, Virginia A1 - Dimou, Niki A1 - Drew, David A. A1 - Figueiredo, Jane C. A1 - Gallinger, Steven A1 - Giles, Graham G. A1 - Gruber, Stephen B. A1 - Gunter, Marc J. A1 - Harlid, Sophia A1 - Harrison, Tabitha A. A1 - Hidaka, Akihisa A1 - Hoffmeister, Michael A1 - Huyghe, Jeroen R. A1 - Jenkins, Mark A. A1 - Jordahl, Kristina M. A1 - Joshi, Amit D. A1 - Keku, Temitope O. A1 - Kawaguchi, Eric A1 - Kim, Andre E. A1 - Kundaje, Anshul A1 - Larsson, Susanna C. A1 - Marchand, Loic Le A1 - Lewinger, Juan Pablo A1 - Li, Li A1 - Moreno, Victor A1 - Morrison, John A1 - Murphy, Neil A1 - Nan, Hongmei A1 - Nassir, Rami A1 - Newcomb, Polly A. A1 - Obón-Santacana, Mireia A1 - Ogino, Shuji A1 - Ose, Jennifer A1 - Pardamean, Bens A1 - Pellatt, Andrew J. A1 - Peoples, Anita R. A1 - Platz, Elizabeth A. A1 - Potter, John D. A1 - Prentice, Ross L. A1 - Rennert, Gad A1 - Ruiz-Narvaez, Edward A. A1 - Sakoda, Lori C. A1 - Schoen, Robert E. A1 - Shcherbina, Anna A1 - Stern, Mariana C. A1 - Su, Yu-Ru A1 - Thibodeau, Stephen N. A1 - Thomas, Duncan C. A1 - Tsilidis, Konstantinos K. A1 - Duijnhoven, Fränzel J. B. van A1 - Guelpen, Bethany van A1 - Visvanathan, Kala A1 - White, Emily A1 - Wolk, Alicja A1 - Woods, Michael O. A1 - Wu, Anna H. A1 - Peters, Ulrike A1 - Gauderman, W. James A1 - Hsu, Li A1 - Chang-Claude, Jenny T1 - Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk JF - British Journal of Cancer N2 - Background: Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk. Methods: We used data from 28,486 postmenopausal women (11,519 cases and 16,967 controls) of European descent. A PRS based on 141 CRC-associated genetic variants was modeled as a categorical variable in quartiles. Multiplicative interaction between PRS and MHT use was evaluated using logistic regression. Additive interaction was measured using the relative excess risk due to interaction (RERI). 30-year cumulative risks of CRC for 50-year-old women according to MHT use and PRS were calculated. Results: The reduction in odds ratios by MHT use was larger in women within the highest quartile of PRS compared to that in women within the lowest quartile of PRS (p-value = 2.7 × 10−8). At the highest quartile of PRS, the 30-year CRC risk was statistically significantly lower for women taking any MHT than for women not taking any MHT, 3.7% (3.3%–4.0%) vs 6.1% (5.7%–6.5%) (difference 2.4%, P-value = 1.83 × 10−14); these differences were also statistically significant but smaller in magnitude in the lowest PRS quartile, 1.6% (1.4%–1.8%) vs 2.2% (1.9%–2.4%) (difference 0.6%, P-value = 1.01 × 10−3), indicating 4 times greater reduction in absolute risk associated with any MHT use in the highest compared to the lowest quartile of genetic CRC risk. Conclusions: MHT use has a greater impact on the reduction of CRC risk for women at higher genetic risk. These findings have implications for the development of risk prediction models for CRC and potentially for the consideration of genetic information in the risk-benefit assessment of MHT use. KW - Dickdarmkrebs KW - Krebsrisiko KW - Menopause KW - Hormontherapie Y1 - 2024 UN - https://nbn-resolving.org/urn:nbn:de:bsz:960-opus4-30989 SN - 0007-0920 SS - 0007-0920 U6 - https://doi.org/10.25968/opus-3098 DO - https://doi.org/10.25968/opus-3098 SP - 10 S1 - 10 ER -